AIRNA Announces Appointment of Matthew Hawryluk
AIRNA, a leading biotech firm specializing in innovative RNA editing therapeutics, has recently appointed Matthew Hawryluk, Ph.D., MBA, to the position of Chief Business Officer. This strategic addition is part of AIRNA's initiative to enhance its leadership team and drive the development of therapeutic solutions aimed at treating both rare and common diseases.
Expertise of Dr. Matthew Hawryluk
Dr. Hawryluk brings a wealth of experience in the life sciences field, underscored by a successful history of combining scientific innovation with commercial success. According to Kris Elverum, President and CEO of AIRNA, Hawryluk's experience in fostering collaborations and managing high-performing teams makes him a valuable addition at this pivotal moment in the company’s growth.
A Transformative Time for AIRNA
With the company on the verge of introducing its first RNA editing therapeutic to clinical trials, Dr. Hawryluk's expertise is crucial. The therapeutic aims to tackle alpha-1 antitrypsin deficiency at the genetic level, offering a novel solution to patients who have been underserved by current treatment options.
Background and Achievements
Before joining AIRNA, Dr. Hawryluk served as Executive Vice President and Chief Business Officer at Gritstone bio, where he was instrumental in forming strategic partnerships and leading business development initiatives. His previous roles at Foundation Medicine equipped him with valuable insights into corporate and business development, while his positions at Thermo Fisher Scientific provided a diverse background in product management, strategy, and marketing across various divisions.
Recognition and Leadership
Dr. Hawryluk is also a board member for Predictive Oncology (NASDAQ: POAI) and Pear Bio, showcasing his active involvement in the biotech sector. His recognition as one of PharmaVoice’s 2023 Standout Execs further highlights his contributions and impact within the industry.
Vision for RNA Editing and Patient Solutions
In expressing his enthusiasm for the role, Dr. Hawryluk noted, "I was drawn to AIRNA because of its bold mission to harness RNA editing as a functional cure for a wide range of diseases." His vision emphasizes the potential for AIRNA to not only reverse genetic mutations responsible for diseases but also to introduce validated healthy genetic variants that can help mitigate disease progression.
New Additions to the Leadership Team
Alongside Dr. Hawryluk's appointment, AIRNA also welcomed Colleen Tucker as Head of People. With her extensive background in human resources across the biotech industry, Ms. Tucker is expected to implement key strategies that align with the company’s overarching goals. Her past leadership roles at various biopharmaceutical companies have prepared her well for the challenges and opportunities at AIRNA.
Pioneering RNA Editing Therapeutics
AIRNA stands at the forefront of RNA editing discoveries that aim to transform patient lives. Their proprietary RESTORE+™ platform is built on pioneering research conducted by esteemed academic co-founders, Thorsten Stafforst from the University of Tübingen and Jin Billy Li from Stanford University. Together, they have collaboratively developed a precise method for the editing of RNA, targeting genetic disorders.
Current Focus and Future Aspirations
The company's lead initiative is focused on addressing alpha-1 antitrypsin deficiency, a genetic condition with significant unmet medical needs. By advancing a robust pipeline of therapies, AIRNA aims to bring new hope to patients battling multiple genetic disorders. Headquartered in Cambridge, MA, with research operations in Tübingen, Germany, AIRNA is positioned to make a significant impact in the field of RNA editing.
Frequently Asked Questions
What is AIRNA's primary focus?
AIRNA specializes in RNA editing therapeutics aimed at addressing inherited disorders and other diseases.
Who is Matthew Hawryluk?
Matthew Hawryluk is AIRNA's new Chief Business Officer with extensive experience in the life sciences sector.
What is the significance of RNA editing?
RNA editing offers a promising approach for precise treatment of genetic disorders, providing the flexibility of biologic therapies.
Where is AIRNA located?
AIRNA has its headquarters in Cambridge, MA, with additional research operations in Tübingen, Germany.
What is the goal of AIRNA's lead program?
The lead program of AIRNA focuses on addressing alpha-1 antitrypsin deficiency and aims to provide innovative therapeutic solutions.
